An enhanced version of Semax with acetyl and amide modifications for improved stability, potency, and nasal absorption.
N-Acetyl Semax (sometimes called N-Acetyl Semax Amidate or NASA) is a chemically modified version of the neuropeptide Semax. The N-terminal acetylation and C-terminal amidation modifications protect the peptide from enzymatic degradation (aminopeptidases and carboxypeptidases), significantly increasing its half-life and bioavailability via the nasal route.
These modifications are reported to enhance the nootropic (cognitive-enhancing) effects of Semax while maintaining its neuroprotective properties. Users and clinicians report stronger, more sustained cognitive effects compared to unmodified Semax — though formal comparative clinical trials are lacking.
N-Acetyl Semax retains the BDNF-enhancing, dopaminergic, and neuroprotective mechanisms of standard Semax while potentially crossing the blood-brain barrier more efficiently due to its modified pharmacokinetic profile.
Acetylation and amidation are well-established peptide modification strategies that improve stability and potency. Limited formal studies specifically on N-Acetyl Semax exist — most evidence derives from the parent Semax compound's research base plus pharmacological principles of peptide modification.
Anecdotal and clinical reports suggest enhanced cognitive effects including improved focus, memory, and verbal fluency compared to standard Semax. The modifications are expected to increase intranasal bioavailability.
📚 Key Reference: PMID: 22943340 (Semax BDNF effects — parent compound)
Expected to be similar to standard Semax with potentially longer duration of effects. Nasal administration is generally well-tolerated. Not FDA-approved. Consult your provider.
NOT FDA-approved. Research use only. More limited data than standard Semax.